Printable Retatrutide Dose Chart
Printable retatrutide dose chart: every trial dose step in mL and U-100 syringe units for 5 to 60 mg vials and 1, 2 or 3 mL of water, one vial per page.
Prints one vial per page, without the site header, menu or footer.
10 mg vial
U-100 insulin syringe: 100 units = 1 mLThe trial dose steps in mL and syringe units, for each amount of bacteriostatic water you could add. Trials started at 2 mg and stepped up every 4 weeks.
| Dose | Doses in vial | 1 mL water10 mg/mL | 2 mL water5 mg/mL | 3 mL water3.33 mg/mL |
|---|---|---|---|---|
| 2 mg | 5 | 20 units0.20 mL | 40 units0.40 mL | 60 units0.60 mL |
| 4 mg | 2 | 40 units0.40 mL | 80 units0.80 mL | 120 units1.20 mL, more than 1 mL |
| 6 mg | 1 | 60 units0.60 mL | 120 units1.20 mL, more than 1 mL | 180 units1.80 mL, more than 1 mL |
| 9 mg | 1 | 90 units0.90 mL | 180 units1.80 mL, more than 1 mL | 270 units2.70 mL, more than 1 mL |
| 12 mg | vial too small | - | - | - |
"Doses in vial" is how many whole doses the milligrams cover. FDA says to discard a multi-dose vial 28 days after first use, so at one dose a week only 4 or 5 of them are usable. A reading above 100 units is more than a 1 mL syringe holds.
Retatrutide is investigational and not approved anywhere. This chart only converts milligrams to syringe markings. It doesn't say what dose to take, and it assumes the vial holds what the label says. Check any dose and your mix with a prescriber or pharmacist. retatrutide360.com/calculator/dose-chart/
The printable retatrutide dose chart above shows, for each vial from 5 to 60 mg, how many mL and how many U-100 syringe units each trial dose step comes to with 1, 2 or 3 mL of bacteriostatic water. A 10 mg vial mixed with 1 mL puts 2 mg at 20 units, for example. Pick a vial, press print, and you get one page per vial without the site menu or footer.
Retatrutide is still investigational. As of October 2026, Lilly has reported six positive Phase 3 trials, no approved version exists, and Lilly's latest release says it "cannot be legally sold or marketed for human use". We found no mixing or dosing instructions from Lilly. This chart only converts milligrams to syringe markings, with the same math as our dose calculator.
Where the numbers come from
The dose steps are the ones in the Phase 3 trials. Everyone started at 2 mg and stepped up every 4 weeks: 4 mg via 2 mg, 9 mg via 2, 4 and 6 mg, and 12 mg via 2, 4, 6 and 9 mg (Lilly's TRIUMPH-1 release). The chart lists 2, 4, 6, 9 and 12 mg for that reason.
The math is three lines. Concentration is the vial's milligrams divided by the water in mL. Volume is the dose divided by the concentration. Units are the volume times 100, because a U-100 syringe has 100 units to the mL. A 30 mg vial with 3 mL is 10 mg per mL, and 6 mg is 0.6 mL, or 60 units.
| Vial | Water | 2 mg | 6 mg | 12 mg |
|---|---|---|---|---|
| 10 mg | 1 mL | 20 units | 60 units | vial too small |
| 20 mg | 2 mL | 20 units | 60 units | 120 units, does not fit |
| 60 mg | 3 mL | 10 units | 30 units | 60 units |
The "doses in vial" column counts whole doses by milligrams. FDA says to discard a multi-dose vial 28 days after first use, so at one dose a week only 4 or 5 of them are usable. The vial sizes guide shows how that plays out for each size.
How to use a printed chart
Print the page for your vial, then write the water you added and the date you mixed it at the top. The chart can't know how much water went in, so a wrong note there means a wrong reading. A printed line at 20, 25 or 50 units is easier to hit than 13.33. If the chart gives a number like that, a different amount of water may put the dose on a clearer line.
The mistake FDA documented most often with compounded semaglutide was a unit mix-up. Patients drew up to 5 to 20 times the intended dose from a multi-dose vial, mostly because they weren't sure how to read the syringe. That was semaglutide, not retatrutide, but the arithmetic is the same. Check the reading with a prescriber or pharmacist before the first draw.
What it can't tell you
- What dose to take. That is for a doctor, and no approved retatrutide label exists.
- Whether the vial holds what its label says. The TGA tested a vial sold as retatrutide and found no retatrutide, plus undeclared semaglutide at about 8 times the level in approved products.
- How long a mixed vial stays good. We found no published stability data, so the 28-day line is FDA's general rule for multi-dose vials.
For the same trial doses in a table without the syringe math, see the dosage chart. For other readings, the units guide and the reconstitution calculator work backward from a unit target to the water you add.
Frequently asked questions
How many units is 2 mg of retatrutide?
It depends on the vial and the water. A 10 mg vial mixed with 1 mL is 10 mg per mL, so 2 mg reads as 20 units. With 2 mL it is 5 mg per mL, so 2 mg reads as 40 units. Same drug, same dose, different markings. The chart lists every combination.
Which retatrutide doses does the chart cover?
The steps from the Phase 3 trials: 2, 4, 6, 9 and 12 mg. Everyone in those trials started at 2 mg and stepped up every 4 weeks, to 4, 9 or 12 mg depending on the arm. The chart converts those milligrams to syringe markings. It doesn't recommend a dose.
Can I print just one vial size?
Yes. Pick the vial above the chart and press print. Each vial gets its own page, and the site header, menu and footer are left off. Choose All vials to print eight pages.
Why do some readings say more than 1 mL?
A 1 mL U-100 syringe holds 100 units. A 10 mg vial mixed with 2 mL puts 4 mg at 80 units, but 6 mg would need 120 units, which doesn't fit. A stronger mix or a bigger vial would, so check the options with a prescriber or pharmacist.
Does the chart work for pens or other syringes?
No. It assumes a freeze-dried vial mixed with bacteriostatic water and a U-100 insulin syringe, where 100 units equal 1 mL. No retatrutide pen is sold legally anywhere.
Sources
- Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial (TRIUMPH-1 topline). Eli Lilly and Company (PR Newswire), 2026. prnewswire.com
- FDA's concerns with unapproved GLP-1 drugs used for weight loss. U.S. Food and Drug Administration, 2026. fda.gov
- FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. U.S. Food and Drug Administration, 2024. fda.gov
- TGA tests counterfeit retatrutide product following serious adverse event report. Therapeutic Goods Administration, 2026. tga.gov.au